EARLY INVESTOR WINDOW CLOSING IN: 
 Days
 Hours

Healthcare Is Broken Because Healthcare Data Is Broken

We’re fixing it by putting physicians and patients back in control

$12Security Price
$972Min. Investment
(+ A 3.5% investor processing fee)

Our CEO and Co-Founder explains why RegenMed is at a key inflection point in disrupting the enormous market opportunities in healthcare data.

Early investors can receive up to 25% bonus shares.

Why Healthcare Needs RegenMed Right Now

Healthcare is at a tipping point: soaring costs, eroding trust, worsening outcomes.  Physicians, patients and even AI systems don’t know what’s true — because unbiased, trustworthy and clinically meaningful data is unavailable.

Data is Compromised

Today’s healthcare data is ingested, “structured”, and “cleansed” by third parties.  Often for their specific commercial purposes.

Data is Fragmented

Most data is incoherent, incomplete, and stale.  It lacks clinically relevance as well as correlated outcomes. 

Data is siloed

Data is inaccessible to those who most need it — physicians and their patients.  It is expensive, and unverifiable.

* Illustrative Data Only

RegenMed partners with physician groups in any specialty to generate unbiased, high-quality datasets which deliver clinical, scientific, and financial return on investment.



Trustworthy datasets supporting clinical decision-making, medical innovation, and patient education. 

How RegenMed Works — And Why It’s Working

RegenMed transforms real-world clinical data into valuable insights — by giving physicians and patients ownership of the process.  Our SaaS platform, Circles™, is live, secure, and used globally.

What We Do

Convert real-world data into broad clinical and scientific impact
Ensure ownership and benefit for physicians and patients
Minimize burden and cost for busy clinicians

How It Works

Proprietary Circles model designed by and for physicians
Robust, patented technical infrastructure + excellent physicians and patient UX
SaaS.  Licensing.  Scalability.  24/7 access.

Why It’s Working

Proven ROI, strong network effects
Used by providers, product companies, and researchers.
Growing ARR and pipeline
Learn how RegenMed makes money — and why it’s working.  Our Business Model in 2 Minutes.

Our Team

Founders

J. William Futrell, M.D.

Co-Founder, Chairman Emeritus

"During my many decades of medical practice, Circles would have been immensely helpful in supporting clinical decision-making, and collaborating with peers."

Michael Tierney

Co-Founder, CEO and Director

"A unicorn company requires large market opportunities, a disruptive product with competitive moats, and seasoned leadership.  We are proud of what we have already built, and excited about where we are going."

Leadership

Peter Johnson, M.D.

Former President and CEO, Cell X
Technologies, Inc.

Kenneth R. Zaslav, M. D.

Director, Center for Regenerative Orthopedic Med

Claude “T.” Moorman, III, M.D.

President, Atrium Health Musculoskeletal Institute

Bert R. Mandelbaum, M.D.

Co-Chair of Medical Affairs, Cedars-Sinai Kerlan-Jobe Institute

John G. Kennedy, M.D., F.R.C.S.

Director of the Foot and Ankle Center at NYU Langone

Christian Jorgensen, M.D., Ph.D.

Professor and Director of the Institute for Regenerative Med...

Laura Prey

Director

Dolph Courchaine

Chief Information Technology Officer

Daniel A. Grande, Ph.D.

Director of Operations/Orthopaedic res. at Feinstein Institute

What's Next for RegenMed — And Why It Matters to Investors

Strategic Roadmap

Dive deeper into how we plan to exploit our market opportunities and traction to build a unicorn company.

Why Invest Now

The healthcare data market and RegenMed are both at inflection points.  Physicians, patients, governments, researchers and AI all need better quality, lower cost data.  Circles deliver it.  Our model is working — high gross margin, global customers, growing recurring revenues, issued  patents, strong channel partners.  Wise investments are about timing.  The timing is right for RegenMed, and the large markets it is addressing.



To learn more about what it takes to build a billion-dollar company, and why we believe RegenMed can be such a company, watch the two short videos below.

Here’s how RegenMed fits the model of every breakout tech company you’ve ever wished you’d backed.
Learn what makes RegenMed unique.

Early Investors Receive Up to 25% Bonus Shares

This is some text inside of a div block.

Bonus shares stack! If you invest $15,000 in the first 45 days, you’ll receive 20% + 5% = 25% more shares in total.

Client Testimonials

RegenMed gave us the evidence we needed — not just data points, but decision-grade insights.

Peter Everts, PhD, FRSM
Medical Researcher and Data Partner 

The Circles platform is incredibly user-friendly, seamlessly automating patient data collection for our analysis.

Grant Pagdin, M.D.  |  Pagdin Health

RegenMed — natural partner with turnkey platforms and experience.

Imran Siddiqui, M.D.  |  ROSM

RegenMed is a valuable ally in our effort to collect reliable and objective medical data.

Dr. Tsoukas  |  IARMES

The testimonials presented are the opinions of the individuals providing them. They may not represent the experience of all clients or investors and are not a guarantee of future performance or success.  No compensation was provided for these testimonials unless explicitly stated

FAQ's

What if the company doesn’t meet its funding goal?

Your investment is only processed if the minimum funding threshold is met.

Can I change my mind after investing?

Yes — federal regulations allow a cancellation window. Here’s how it works.

When do I get my investment back?

Early-stage investing is long-term. This is about owning a piece of the future — not a quick flip.

follow our updates for investors

Join The Discussion